Navigation Links
Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002
Date:6/15/2009

ct candidates. As part of that transaction, Alexza licensed to Symphony Allegro its Staccato loxapine program and its Staccato alprazolam program. Since that time, Alexza has been conducting the clinical development of AZ-004 for the acute treatment of agitation, AZ-104 for the acute treatment of migraine headache, and AZ-002 for the treatment of acute panic attacks, with the funds provided by Symphony Allegro.

"In the past 30 months, we have conducted 14 clinical trials with the three product candidates that were licensed into Symphony Allegro. This is a remarkable development achievement, by almost any standard. Moreover, we plan to submit Alexza's first NDA for AZ-004, Staccato loxapine, in the first quarter of 2010. Symphony Capital and RRD International have been a very important part of these accomplishments," said Thomas B. King, Alexza President and CEO. "With the closing of the purchase of Symphony Allegro, we will re-acquire full ownership of AZ-004, AZ-104 and AZ-002. In our partnership with Symphony Allegro, the intended development of these product candidates has been achieved and, assuming our stockholders approve the transaction, Symphony Capital and its investors will be able to share in the future benefits of the advancement of these product candidates."

Mark Kessel, Managing Director of Symphony Capital, added, "We are pleased to have been a part of this collaboration which provided capital and development assistance to enable Alexza to advance these product candidates to the point they are today. The terms of the agreement we have announced today continue to reflect the confidence that we have in Alexza and its management."

Conference Call Information

Alexza will host a conference call tomorrow morning, June 16, 2009, at 9:00 a.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call, replay and w
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
2. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
3. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
4. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
5. Alexza to Webcast Investor and Analyst Day Presentations
6. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
7. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
8. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
9. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
10. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
11. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 2013 The legal team at Pulaski ... a concerted effort to connect women and families coping ... drugs Yaz, Yasmin & Ocella with the legal representation ... on the notorious birth control drugs as well as ... , Yaz, Yasmin & Ocella were very popular birth ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Daily Gossip issued ... a new review on their page. John Colston, Daily Gossip’s ... to Shaun Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan ... sustain that carbs are healthy at a time when nutritionists ... from highly caloric products. , The diet is based ...
(Date:5/18/2013)... Also known as bariatric surgery , ... surgery that guarantees patients long-term weight loss. Dr. Naim ... give readers a brief tutorial on this revolutionary weight ... New York City’s Mount Sinai School of Medicine. After ... fellowship in Minimally Invasive Bariatric Surgery. He has also ...
(Date:5/18/2013)... Children who swallow high-powered magnets often need surgery and ... a new study. The researchers, from the Louisiana ... more than 79 percent of children who swallowed very ... procedure, in which a tube containing a camera is ... these cases can be treated through observation or by ...
(Date:5/18/2013)... There are significant cost and risk factors ... or treat gastrointestinal problems, according to research presented ... study by New York Presbyterian Hospital and Weill-Cornell ... substantially reduce the cost and risk of managing ... to affect nearly 25 percent of adults, researchers ...
Breaking Medicine News(10 mins):Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2
... , TUESDAY, Aug. 16 (HealthDay News) -- For some ... of the disease who find standard treatments either intolerable ... relief. A new injectable treatment called pegloticase (brand ... patients, but researchers say that for the roughly ...
... Pneumonia kills more children around the world than any ... the causes of childhood pneumonia across many countries was ... study called the Pneumonia Etiology Research for Child Health ... 5 African and 2 Asian research sites coordinated by ...
... was a dramatic increase in the number of children,s flu-related hospital ... agency says. Over that time, flu rose from 65th to ... younger go to the hospital, according to a report from the ... found that skin infections rose from 13th to 7th in the ...
... Foundation launched a major new collaboration created with ... with its announcement that it will provide funding ... interventional radiology during 2012󈝹 in the Howard Hughes ... "The SIR Foundation, which seeks to further ...
... new study has shown the Flexible-Fiber CO2 laser to ... (TSC) without the,line of sight problems encountered with conventional ... Medical Center (BMC) and Boston University School of Medicine ... Neurosurgery . This is the first study to report ...
... for 15 minutes a day, or 92 minutes per week, ... who are inactive, according to a study published today in ... reduced deaths from any cause by 14 percent," said study ... The University of Texas MD Anderson Cancer Center Department of ...
Cached Medicine News:Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 2Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 3Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 4Health News:Largest global childhood pneumonia etiology study launched 2Health News:Largest global childhood pneumonia etiology study launched 3Health News:Society of Interventional Radiology Foundation funds Howard Hughes Medical Institute Award 2Health News:Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery 2Health News:Study finds 15 minutes of moderate daily exercise lengthens life 2Health News:Study finds 15 minutes of moderate daily exercise lengthens life 3
(Date:5/17/2013)... Research explores data on ... also   to   be presented ... the global specialty biopharmaceutical company, announces that it will ... American Psychiatric Association (APA) 166th Annual Meeting in ... being presented represent Shire,s ongoing commitment to the clinical ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The ... recombinant proteins, is placing renewed emphasis on alternate ... rise as a number of factors are converging ... pharmaceutical makers and their delivery device partners . ... refractory conditions, the growing trend toward self-administration for ...
(Date:5/17/2013)... , May 17, 2013  Boehringer Ingelheim ... respiratory disease at the American Thoracic Society International ... , May 17 – 22. ... approved for the treatment of chronic obstructive pulmonary ... as well as investigational compounds for asthma, idiopathic ...
Breaking Medicine Technology:Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8
... As part of a three-year global initiative to identify ... problems around the world, Boehringer Ingelheim and Ashoka,s Changemakers® ... Health: Achieving Individual, Family, and Community Well-Being ... the most innovative models and solutions that are transforming ...
... Ascension Orthopedics, Inc., a world leader in PyroCarbon orthopedic ... Glenoid. The Mini Glenoid is yet another addition to the ... way to address glenoid arthritis. "The Mini ... the glenoid as well as load-share with the peripheral glenoid ...
Cached Medicine Technology:Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition 2Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition 3Ascension Orthopedics Announces Market Release of TITAN™ Inset Mini Glenoid 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: